|
Home : Unsafe Drugs : Avandia : Wikipedia : Rosiglitazone Wikipedia - Rosiglitazone
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Annual sales peaked at approx $2.5bn in 2006, but declined after reports of adverse effects. The drug's patent expires in 2012.[1] Some reports have suggested that rosiglitazone is associated with a statistically significant risk of heart attacks, but other reports have disagreed, and the controversy has not been resolved. Concern about adverse effects has reduced the use of rosiglitazone despite its sustained effects on glycemic control.[2] The drug is currently the subject of many lawsuits against GSK. Over 13,000 have been brought against the company due to the drug. [3] As of July 2010, GSK has agreed to settlements on more that 11,500 of these suits. The drug is controversial in the U.S. Food and Drug Administration. Some reviewers concluded that rosiglitazone caused more deaths than pioglitazone (Actos) and recommended that rosiglitazone be taken off the market, but an F.D.A. panel disagreed and it remains on the market in the U.S.[4]
[edit] PharmacologyRosiglitazone is a member of the thiazolidinedione class of drugs. Thiazolidinediones act as insulin sensitizers. They reduce glucose, fatty acid, and insulin blood concentrations. They work by binding to the peroxisome proliferator-activated receptors (PPARs). PPARs are receptors on the membrane of the cell nucleus. Thiazolidinediones enter the cell, bind to the nuclear receptors, and affect the expression of DNA. There are several PPARs, including PPARα, PPARβ/δ, and PPARγ. Thiazolidinediones bind to PPARγ. PPARs are expressed in fat cells, cells of the liver, muscle, heart, and inner wall (endothelium) and smooth muscle of blood vessels. PPARγ is expressed mainly in fat tissue, where it regulates genes involved in fat cell (adipocyte) differentiation, fatty acid uptake and storage, and glucose uptake. It is also found in pancreatic beta cells, vascular endothelium, and macrophages.[5] Rosiglitazone is a selective ligand of PPARγ and has no PPARα-binding action. Other drugs bind to PPARα. Rosiglitazone also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Nuclear factor kappa-B (NF-κB) is a signaling molecule which stimulates the inflammatory pathways. NF-κB inhibitor (IκB) is an inhibitor which downregulates the inflammatory pathways. When patients take rosiglitazone, NF-κB levels fall and IκB levels increase.[6] Rosiglitazone may also benefit patients with Alzheimer's disease who do not express the ApoE4 allele.[7] This is the subject of a clinical trial currently underway.[8] Rosiglitazone may also treat mild to moderate Ulcerative Colitis, due to its antiinflammatory properties as a PPAR ligand.[9] A clinical trial has suggested that these agents may be of use in treating malaria.[10] [edit] Side-effects and contraindications[edit] Heart diseaseSome studies conclude that rosiglitazone increases fatalities from heart disease, but other studies do not. A meta-analysis reported in May 2007 that the use of rosiglitazone was associated with a significantly increased risk of heart attack (odds ratio=1.43, (95% confidence interval, 1.03 to 1.98; P=0.03)), and an even higher risk of death from all cardiovascular diseases (odds ratio=1.64).[11] The U.S. Food and Drug Administration (FDA) issued an alert on May 21, 2007.[12] On July 30, 2007 an Advisory Committee of the Food and Drug Administration concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of myocardial ischemic events (including heart attacks) than a placebo, but data from several long term, prospective clinical trials showed that when rosiglitazone was compared to metformin, or sulfonylurea, there was no difference in the risk of heart attack. This data, coupled with the meta-analysis, prompted the FDA to state that the data on the association between rosiglitazone and myocardial ischemia were inconclusive. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate this, and several other reports have failed to conclude the controversy. This weak evidence for adverse effects has dramatically reduced the use of rosiglitazone, despite its important and sustained effects on glycemic control.[2] In 2009 the RECORD study, an open label trial published in the Lancet, found that there was no increase in cardiovascular hospitalisation or death with rosiglitazone compared to metformin plus sulfonylurea, but the rate of heart failure causing admission to hospital or death was significantly increased.[13] Both TZD's are contraindicated in patients with NYHA Class III and IV heart failure. In February 2010, David Graham, the FDA's associate director of drug safety, recommended that rosiglitazone be taken off the market. Graham argued that rosiglitazone caused 500 more heart attacks and 300 more heart failures than its main competitor. At the same time, a report by the Senate Finance Committee accused GlaxoSmithKline of knowing about the drug's risks well before they became public. The report also criticized the FDA for letting clinical trials continue despite 83,000 heart attacks from 1999 to 2007 that the FDA linked to rosiglitazone. GlaxoSmithKline maintains that the drug is safe and that the Senate report did not consider scientific evidence or the company's efforts to make known its concerns to the parties involved. However, the FDA still recommends that patients continue taking it unless their doctor tells them otherwise.[14][15] In June 2010, David Graham et al. published a retrospective study of 227,571 elderly American patients, comparing roziglitazone to pioglitazone, the other thiazolidinedione marketed in the United States. The authors concluded that rosiglitazone was associated with "an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older" [16]. The number needed to treat with roziglitazone to cause harm in one was sixty. [edit] StrokeAvandia has been linked to stroke. In some studies, it was found that the drug increases the risk of stroke by over 27%.[17][18] [edit] Bone fracturesGlaxoSmithKline reported a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide.[19] The information was based on data from the ADOPT trial.[20] The same increase has been found with pioglitazone (Actos), another TZD. [edit] Eye damageBoth rosiglitazone and pioglitazone have been suspected of causing macular edema, which damages the retina of the eye and causes partial blindness. Blindness is also a possible effect of diabetes, which rosiglitazone is intended to treat. One report[21] documented several occurrences and recommended discontinuation at the first sign of vision problems. [edit] HepatotoxicityModerate to severe acute hepatitis has occurred in several adults who had been taking the drug at the recommended dose for 2–4 weeks. Plasma rosiglitazone concentrations may be significantly increased in patients with pre-existing hepatic impairment.[22] [edit] SalesUS sales of $2.2 billion in 2006.[23] Sales in 2Q 2007 down 22% compared to 2006.[24] 4Q 2007 sales down to $252 million.[25] Though sales have gone down since 2007 due to safety concerns, Avandia sales for 2009 totalled $1.2 billion worldwide.[15] [edit] LawsuitsThe Guardian reports lawsuits over the drug could total anywhere from $1 billion to $6 billion. This is based on research by analysts for UBS, who say 13,000 suits have been filed.[26] Included among those suing: Santa Clara County, California, which claims to have spent $2 million on rosiglitazone between 1999 and 2007 at its public hospital and is asking for "triple damages".[27] In May 2010, GlaxoSmithKline (GSK) reached settlement agreements for some of the cases against the company, agreeing to pay $60 million to resolve 700 suits.[28] In July 2010, GSK reached settlement agreements to close another 10,000 of the lawsuits against it, agreeing to pay about $460 million to settle these suits.[29][30] In a statement, Michael Miller, the attorney representing 1,500 patients in the suit, said about the settlement "It's a compromise that allows both sides to put this behind them and move on."[31] [edit] US Government InvestigationThe FDA began investigating the drug, but following a 2007 study, an FDA advisory panel agreed that Avandia does raise risks to the heart. However, the FDA voted to keep the drug on the market. A few months later the agency added a black-box warning about potential heart risks of Avandia.[32] GlaxoSmithKline is currently being investigated by the FDA and the US Congress regarding Avandia. Senators Democrat Max Baucus and Republican Charles Grassley filed a report urging GSK to withdraw Avandia in 2008 due to the side effects. The report cited that the drug caused 500 avoidable heart attacks a month and that Glaxo officials sought to intimidate doctors who criticized the drug. It also said that GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke.[33] The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alledged by the Senate committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals.[34] GSK defended itself by presenting data that its own tests found Avandia to be safe. Although an FDA staff report showed that the conclusions were flawed.[35] Many studies have found the drug to have serious safety concerns.[36] On July 14, 2010, after extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. 12 members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and 3 voted to keep it on the market with the current warning label.[37][38] [edit] References
[edit] External links
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rosiglitazone". Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|
Looking for a District of Columbia Avandia attorney? Get in touch with one of our District of Columbia Avandia attorneys now.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- Do you Need a Lawyer
- Do you Have a Case? |
- Avandia Lawyers and Lawsuites |
- Avandia Information |
- Home |
- Home |
- Contact Us |
- Find an Attorney |
- Legal Issues |
- Disclaimer |
- Site Map |
- RSS
LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.
The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.
Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.
20120206-214413
Close (x)
Looking for an Attorney?
Close
(x)
 |
Find Legal Help for Your Avandia Case - Submit Your Information Below |
Do you need legal assistance with your Avandia case?
|
 |
|
This form is secure and encrypted. More information about secure forms and your privacy here.
|